Last reviewed · How we verify
Adefovir/Entecavir
Adefovir and entecavir are nucleoside/nucleotide reverse transcriptase inhibitors that block hepatitis B virus (HBV) replication by inhibiting viral polymerase.
Adefovir and entecavir are nucleoside/nucleotide reverse transcriptase inhibitors that block hepatitis B virus (HBV) replication by inhibiting viral polymerase. Used for Chronic hepatitis B infection, Lamivudine-resistant hepatitis B (adefovir).
At a glance
| Generic name | Adefovir/Entecavir |
|---|---|
| Also known as | Baraclude, BMS-200475 |
| Sponsor | Bristol-Myers Squibb |
| Drug class | Nucleoside/nucleotide reverse transcriptase inhibitor |
| Target | Hepatitis B virus polymerase (reverse transcriptase) |
| Modality | Small molecule |
| Therapeutic area | Virology/Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Both drugs are nucleoside analogues that are phosphorylated intracellularly and incorporated into the growing HBV DNA chain, causing chain termination and preventing viral replication. Entecavir is a guanosine analogue with higher potency and lower resistance rates compared to adefovir. Adefovir is an adenosine monophosphate analogue that also inhibits HBV polymerase with activity against lamivudine-resistant strains.
Approved indications
- Chronic hepatitis B infection
- Lamivudine-resistant hepatitis B (adefovir)
Common side effects
- Headache
- Fatigue
- Nausea
- Elevated creatinine/renal dysfunction (adefovir)
- Lactic acidosis (rare)
Key clinical trials
- Halting Nucleoside Analogues in Chronic Hepatitis B (NA)
- Carvedilol for Prevention of Esophageal Varices Progression (NA)
- Hepatitis B Virus (HBV) Viral Suppression by Entecavir in Adefovir Partial Responders
- Effects of Antiviral Therapy on Patients With HBV-related HCC
- Extension Study of Carvedilol RCT Study (NA)
- Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Participants With Chronic Hepatitis B (PHASE2)
- Real World Study About Anti-viral Regimen Adjustment on Achieving Complete Response in CHB Patients
- Improvement of Hard Endpoint in Chronic Hepatitis B Patients Treated With Antiviral Therapy
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adefovir/Entecavir CI brief — competitive landscape report
- Adefovir/Entecavir updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI